Get the Stockscreener App
2.50
0.40%
-0.010
After Hours:
2.50
Nuvation Bio Inc stock is traded at $2.50, with a volume of 3.72M.
It is down -0.40% in the last 24 hours and up +32.98% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$2.51
Open:
$2.5
24h Volume:
3.72M
Relative Volume:
0.65
Market Cap:
$850.66M
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-7.1429
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
+8.70%
1M Performance:
+32.98%
6M Performance:
-0.79%
1Y Performance:
-32.25%
1-Day Range:
$2.46
$2.57
1-Week Range:
$2.32
$2.62
52-Week Range:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.50 | 854.06M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
What drives Nuvation Bio Inc. stock priceSuperior stock growth - PrintWeekIndia
Published on: 2025-07-25 18:05:03 - PrintWeekIndia
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - BioSpace
Is Nuvation Bio Inc. a good long term investmentFree Consultation - Autocar Professional
Nuvation Bio Inc. Stock Analysis and ForecastFree Stock Index Interpretation - Autocar Professional
What analysts say about Nuvation Bio Inc. stockTremendous gains - jammulinksnews.com
Bullish Nuvation Bio Insiders Loaded Up On US$2.31m Of Stock - 富途牛牛
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma - TipRanks
Will Nuvation Bio Inc. stock benefit from interest rate changesLong Term Low Risk Growth - Newser
Is Nuvation Bio Inc. stock a good hedge against inflationFree Investing Community - Newser
Why Nuvation Bio Inc. stock attracts strong analyst attentionLow Risk Entry Points - beatles.ru
Nuvation Bio's Mysterious 5% Surge: A Deep Dive into the Unseen Drivers - AInvest
What makes Nuvation Bio Inc. stock price move sharplyIntraday Trade Ideas - Newser
How Nuvation Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy - MSN
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Nuvation Bio's 16% Surge: A Deep Dive Into the Unseen Drivers - AInvest
Nuvation Bio's 11% Spike: A Deep Dive into the Unseen Drivers - AInvest
Nuvation Bio’s 7% Surge: A Technical and Market Flow Deep-Dive - AInvest
Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects - Investing.com
Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year - simplywall.st
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating - MSN
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans - MSN
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2500 Growth Index - MarketScreener
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2000 Growth Index - MarketScreener
Digging for Diamonds in Biotech: Why Insider Buys Signal Opportunity in Nuvation Bio and Ardelyx - AInvest
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio stock rating reiterated at Market Outperform by Citizens JMP - Investing.com South Africa
Nuvation Bio's Taletrectinib Emerges as a Niche Oncology Leader with NCCN Endorsement - AInvest
Nuvation Bio (NUVB) Gains NCCN Endorsement for Taletrectinib in - GuruFocus
Nuvalent chases after Nuvation in ROS1 lung cancer - pharmaphorum
Nuvation Bio's Mysterious 10% Surge: A Technical & Market Flow Deep Dive - AInvest
Nuvation Bio jumps after insiders purchase shares worth over $1.1M - MSN
Nuvation Bio's Insider Buying Surge: A Signal of Biotech Momentum Ahead? - AInvest
Wealth Enhancement Advisory Services LLC Buys Shares of 10,140 Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):